- Home
- SENEA vs QURE Comparison
SENEA vs QURE Comparison
Compare SENEA & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEA
- QURE
- Stock Information
- Founded
- SENEA 1949
- QURE 1998
- Country
- SENEA United States
- QURE Netherlands
- Employees
- SENEA N/A
- QURE N/A
- Industry
- SENEA Packaged Foods
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- SENEA Consumer Staples
- QURE Health Care
- Exchange
- SENEA Nasdaq
- QURE Nasdaq
- Market Cap
- SENEA 699.2M
- QURE 725.4M
- IPO Year
- SENEA N/A
- QURE 2007
- Fundamental
- Price
- SENEA $104.32
- QURE $16.18
- Analyst Decision
- SENEA
- QURE Strong Buy
- Analyst Count
- SENEA 0
- QURE 10
- Target Price
- SENEA N/A
- QURE $36.90
- AVG Volume (30 Days)
- SENEA 43.5K
- QURE 1.2M
- Earning Date
- SENEA 08-07-2025
- QURE 07-29-2025
- Dividend Yield
- SENEA N/A
- QURE N/A
- EPS Growth
- SENEA N/A
- QURE N/A
- EPS
- SENEA 6.24
- QURE N/A
- Revenue
- SENEA $1,571,618,000.00
- QURE $14,337,000.00
- Revenue This Year
- SENEA N/A
- QURE N/A
- Revenue Next Year
- SENEA N/A
- QURE $278.91
- P/E Ratio
- SENEA $16.73
- QURE N/A
- Revenue Growth
- SENEA 7.30
- QURE N/A
- 52 Week Low
- SENEA $59.21
- QURE $4.45
- 52 Week High
- SENEA $107.36
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- SENEA 56.28
- QURE 65.00
- Support Level
- SENEA $102.57
- QURE $12.89
- Resistance Level
- SENEA $105.85
- QURE $14.23
- Average True Range (ATR)
- SENEA 2.60
- QURE 1.03
- MACD
- SENEA -0.10
- QURE 0.23
- Stochastic Oscillator
- SENEA 56.26
- QURE 88.91
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.